Granules India Ltd (GRANULES) is currently trading at 841.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Granules India Limited is a vertically integrated pharmaceuticals manufacturer producing APIs, pharmaceutical formulation intermediates (PFIs) and finished dosages, supplying global generic and branded customers and operating subsidiaries across the US, Switzerland and India. Management announced a strategic shift from volume-led generics to higher-value, differentiated products, emphasizing a first-to-file playbook, complex generics, controlled substances, oncology and peptide CDMO as four primary growth engines with visible pipelines and exclusivity opportunities. Granules has materially improved margins and balance sheet strength recently: gross margin expanded ~15 percentage points to 65%, EBITDA margin improved to 22%, R&D intensity rose to ~6% of sales in Q1 FY27, and the company moved into a consolidated net cash position after a preferential allotment. Controlled substances are a clear competitive moat in the U.S.: Granules has become the third largest controlled substance manufacturer by value, holds top-three shares in multiple ADHD products, benefits from rising DEA quotas and API vendor preference, and sees a multi-year runway for market share gains. The company is pursuing a disciplined INR 2,000 crore capex program over three to four years to scale complex generics, oncology, peptide CDMO and US operations, while investing in digitalization and milestone-based capital deployment to de-risk investments and improve ROCE over time.

Over the past 52 weeks, Granules India Ltd has traded between a low of ₹520.05 and a high of ₹922.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Granules India Ltd has a market capitalization of approximately 22,820.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Granules India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 22,820.76 Cr, Granules India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Granules India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Granules India Ltd is 34.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

He sold 1.72 crore Granules India equity shares on September 11, 2026 through block-deal and open-market transactions.

Revenue rose 22% to ₹1,476.8 crore, EBITDA grew 37% to ₹338.9 crore, and PAT increased 60% to ₹180 crore; gross margin was 65.6%.

Granules said its US subsidiary GPI received USFDA approval for an ANDA for Lisdexamfetamine Dimesylate chewable tablets, a generic medication used to treat ADHD.

Granules said its US subsidiary GPI received tentative USFDA approval for its ANDA for Amphetamine Extended-Release Tablets.